It is the policy of the DPC Summit Co-Organizers that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.
The following faculty in a position to control content for this session have disclosed the following relevant financial relationships:
- Thomas White disclosed a relationship with Amarin (Speakers Bureau – Vascepa; Stock), Johnson and Johnson (Stock), and IONIS (Stock).
All other faculty in a position to control content for this session have indicated they have no relevant financial relationships to disclose.
By the end of this educational activity, participants should be better able to:
- Review of current guidelines, with an emphasis on early disease detection and risk factor management.
- Gain familiarity with practical and affordable laboratory testing and imaging which are "do-able" in a DPC setting.
- Commitment to return home with a renewed focus on CVD risk and improved patient care.
Click here to evaluate this session and claim CME.
